241 related articles for article (PubMed ID: 30452281)
1. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Pozzi M; Pisano S; Marano G; Carnovale C; Bravaccio C; Rafaniello C; Capuano A; Rossi F; Rizzo R; Bernardini R; Nobile M; Molteni M; Clementi E; Biganzoli E; Radice S
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):133-140. PubMed ID: 30452281
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
3. No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Schoemakers RJ; van Kesteren C; van Rosmalen J; Eussen MLJM; Dieleman HG; Beex-Oosterhuis MM
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):192-196. PubMed ID: 30672720
[TBL] [Abstract][Full Text] [Related]
4. Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.
Pozzi M; Pisano S; Bertella S; Capuano A; Rizzo R; Antoniazzi S; Auricchio F; Carnovale C; Cattaneo D; Ferrajolo C; Gentili M; Guastella G; Mani E; Rafaniello C; Riccio MP; Scuderi MG; Sperandeo S; Sportiello L; Villa L; Radice S; Clementi E; Rossi F; Pascotto A; Bernardini R; Molteni M; Bravaccio C
J Clin Psychiatry; 2016 Dec; 77(12):e1601-e1609. PubMed ID: 27780333
[TBL] [Abstract][Full Text] [Related]
5. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
6. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Wink LK; Early M; Schaefer T; Pottenger A; Horn P; McDougle CJ; Erickson CA
J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):78-82. PubMed ID: 24564519
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
8. Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder.
Yoon Y; Wink LK; Pedapati EV; Horn PS; Erickson CA
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):822-827. PubMed ID: 27389348
[TBL] [Abstract][Full Text] [Related]
9. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.
Vázquez-Bourgon J; Ortiz-García de la Foz V; Gómez-Revuelta M; Mayoral-van Son J; Juncal-Ruiz M; Garrido-Torres N; Crespo-Facorro B
Int J Neuropsychopharmacol; 2022 Oct; 25(10):795-806. PubMed ID: 35641112
[TBL] [Abstract][Full Text] [Related]
11. Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Mustafa S; Joober R; Iyer S; Shah J; Lepage M; Malla A
J Clin Psychiatry; 2019 Aug; 80(5):. PubMed ID: 31509359
[TBL] [Abstract][Full Text] [Related]
12. Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.
Rafaniello C; Pozzi M; Pisano S; Ferrajolo C; Bertella S; Sportiello L; Carnovale C; Sullo MG; Cattaneo D; Gentili M; Rizzo R; Pascotto A; Mani E; Villa L; Riccio MP; Sperandeo S; Bernardini R; Bravaccio C; Clementi E; Molteni M; Rossi F; Radice S; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):1-8. PubMed ID: 27875914
[TBL] [Abstract][Full Text] [Related]
13. Iron homeostasis during risperidone treatment in children and adolescents.
Calarge CA; Ziegler EE; Del Castillo N; Aman M; McDougle CJ; Scahill L; McCracken JT; Arnold LE
J Clin Psychiatry; 2015 Nov; 76(11):1500-5. PubMed ID: 26301448
[TBL] [Abstract][Full Text] [Related]
14. Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
Martin A; Landau J; Leebens P; Ulizio K; Cicchetti D; Scahill L; Leckman JF
J Child Adolesc Psychopharmacol; 2000; 10(4):259-68. PubMed ID: 11191686
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
Nicol GE; Yingling MD; Flavin KS; Schweiger JA; Patterson BW; Schechtman KB; Newcomer JW
JAMA Psychiatry; 2018 Aug; 75(8):788-796. PubMed ID: 29898210
[TBL] [Abstract][Full Text] [Related]
16. Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression.
Pozzi M; Ferrentino RI; Scrinzi G; Scavone C; Capuano A; Radice S; Nobile M; Formisano P; Clementi E; Bravaccio C; Carnovale C; Pisano S
Eur Child Adolesc Psychiatry; 2022 Jan; 31(1):21-37. PubMed ID: 32617775
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
DeVane CL; Charles JM; Abramson RK; Williams JE; Carpenter LA; Raven S; Gwynette F; Stuck CA; Geesey ME; Bradley C; Donovan JL; Hall AG; Sherk ST; Powers NR; Spratt E; Kinsman A; Kruesi MJ; Bragg JE
Pharmacotherapy; 2019 Jun; 39(6):626-635. PubMed ID: 31063671
[TBL] [Abstract][Full Text] [Related]
18. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics.
de Hoogd S; Overbeek WA; Heerdink ER; Correll CU; de Graeff ER; Staal WG
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):166-73. PubMed ID: 22506734
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.
Calarge CA; Nicol G; Schlechte JA; Burns TL
J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):120-9. PubMed ID: 24725198
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and safety profile of risperidone in a sample of children and adolescents.
Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
